The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: Results from the FACS trial

Objective To evaluate the diagnostic accuracy of a single CEA (carcinoembryonic antigen) blood test in detecting colorectal cancer recurrence. Background Patients who have undergone curative resection for primary colorectal cancer are typically followed up with scheduled CEA testing for 5 years. Decisions to investigate further (usually by CT imaging) are based on single test results, reflecting international guidelines. Methods A secondary analysis was undertaken of data from the FACS trial (two arms included CEA testing). The composite reference standard applied included CT-CAP imaging, clinical assessment and colonoscopy. Accuracy in detecting recurrence was evaluated in terms of sensitivity, specificity, likelihood ratios, predictive values, time-dependent area under the ROC curves, and operational performance when used prospectively in clinical practice are reported. Results Of 582 patients, 104 (17.9%) developed recurrence during the 5 year follow-up period. Applying the recommended threshold of 5μg/L achieves at best 50.0% sensitivity (95% CI: 40.1–59.9%); in prospective use in clinical practice it would lead to 56 missed recurrences (53.8%; 95% CI: 44.2–64.4%) and 89 false alarms (56.7% of 157 patients referred for investigation). Applying a lower threshold of 2.5μg/L would reduce the number of missed recurrences to 36.5% (95% CI: 26.5–46.5%) but would increase the false alarms to 84.2% (924/1097 referred). Some patients are more prone to false alarms than others—at the 5μg/L threshold, the 89 episodes of unnecessary investigation were clustered in 29 individuals. Conclusion Our results demonstrated very low sensitivity for CEA, bringing to question whether it could ever be used as an independent triage test. It is not feasible to improve the diagnostic performance of a single test result by reducing the recommended action threshold because of the workload and false alarms generated. Current national and international guidelines merit re-evaluation and options to improve performance, such as making clinical decisions on the basis of CEA trend, should be further assessed.

[1]  P. Heagerty,et al.  Survival Model Predictive Accuracy and ROC Curves , 2005, Biometrics.

[2]  Paul Ziprin,et al.  Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. , 2009, Surgical oncology.

[3]  R. Pazdur,et al.  Colorectal Cancer: Diagnosis and Management , 2005 .

[4]  R. Perera,et al.  Blood CEA levels for detecting recurrent colorectal cancer. , 2014, The Cochrane database of systematic reviews.

[5]  M. Hellinger,et al.  Reoperation for recurrent colorectal cancer. , 2006, Clinics in colon and rectal surgery.

[6]  D. Mant,et al.  Carcinoembryonic antigen monitoring to detect recurrence of colorectal cancer: how should we interpret the test results? , 2014, Clinical chemistry.

[7]  M. Choti,et al.  NCCN Clinical Practice Guidelines in Oncology: colon cancer. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[8]  J. Guthrie Colorectal cancer: follow-up and detection of recurrence , 2002, Abdominal Imaging.

[9]  E. Martin,et al.  The use of serial CEA determinations to predict recurrence of colon cancer and when to do a second‐look operation , 1978, Cancer.

[10]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[11]  N. Kemeny,et al.  False-positive elevations of carcinoembryonic antigen in patients with a history of resected colorectal cancer. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[12]  D. Mant,et al.  Blood Measurement of Carcinoembryonic Antigen Level for Detecting Recurrence of Colorectal Cancer. , 2016, JAMA.

[13]  R. Fischer,et al.  Eighty-four potential second-look operations based on sequential carcinoembryonic antigen determinations and clinical investigations in patients with recurrent gastrointestinal cancer. , 1985, American journal of surgery.

[14]  D. Sargent,et al.  Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  B. No̸rgaard-Pedersen,et al.  Modelling of serial carcinoembryonic antigen changes in colorectal cancer. , 1993, Scandinavian journal of clinical and laboratory investigation.

[16]  References , 1971 .

[17]  R. Perera,et al.  Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. , 2013, JAMA.